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Background: Patients with rapid progression of carotid intima media thickness (CIMT) were shown to have a
higher future risk for cardiovascular events.
The aim of this study was to investigate the impact of multiple risk factor intervention on CIMT progression and to
establish whether new cardiovascular surrogate measurements would allow prediction of CIMT changes.
Materials and methods: In this prospective, open, 2-years study, we included 97 patients with type 2 diabetes and at
least two insufficiently treated cardiovascular risk factors, i.e. HbA1c > 7.5% (58 mmol/mol); LDL-cholesterol >3.1 mmol/l
or blood pressure >140/90 mmHg. Treatment was intensified according to current guidelines over 3 months with
the aim to maintain intensification over 2 years.
The primary outcome was the change in CIMT after 2 years. We also assessed markers of mechanical and
biochemical endothelial function and endothelial progenitor cells before and after 3 months of treatment
intensification. For testing differences between before and after multifactorial treatment measurements we used
either the paired student’s t-test or the Wilcoxon signed-rank test, depending on the distribution of the data.
Additional, explorative statistical data analysis was done on CIMT progression building a linear multivariate
regression model.
Results: Blood glucose, lipids and blood pressure significantly improved during the first 3 months of intensified
treatment, which was sustained over the 2-year study duration. Mean CIMT significantly decreased from baseline
to 2 year (0.883 ± 0.120 mm vs. 0.860 ± 0.130 mm; p = 0.021). None of the investigated surrogate measures,
however, was able to predict changes in IMT early after treatment intensification.
Conclusions: Intensification of risk factor intervention in type 2 diabetes results in CIMT regression over a period
of 2 years. None of the biomarkers used including endothelial function parameters or endothelial progenitor cells
turned out to be useful to predict CIMT changes.
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Patients with type 2 diabetes face a significantly increased
risk for cardiovascular events as well as mortality com-
pared to subjects without diabetes [1]. The STENO-2
study was the first study which impressively demonstrated
a halving of the risk for cardiovascular events and mortal-
ity by target driven, intensified, multifactorial risk factor
intervention compared to conventional, less stringent risk
factor management [2].
However, epidemiologic data suggest that the cardio-
vascular risk attributable to type 2 diabetes remains about
two-fold increased even after adjustment for established
risk factors such as hyperglycaemia, hypertension or
hyperlipidaemia [3]. Therefore it would be crucial to
identify those subjects with the highest residual risk in
order to intensify preventive therapies.
Common carotid artery intima-media thickness (CIMT),
measured by B-mode ultrasound, is a validated surrogate
measure of preclinical atherosclerosis and was shown
to be a predictor of future cardiovascular events [4].
Recently, in particular rapid progression of CIMT has
been associated with adverse cardiovascular outcome [5].
In addition, CIMT can be assessed quickly, non-
invasively, and inexpensively with high-resolution ultra-
sound and therefore changes in CIMT might be a useful
early measurement of treatment response.
Previous data have shown that statin treatment [6,7]
or blood pressure treatment [8] are able to reduce CIMT
progression, however, whether or not multifactorial risk
factor intervention as recommended by current guidelines
is able to reduce CIMT progression in subjects with type 2
diabetes, has not been investigated yet.
We have performed a study in patients with type 2
diabetes with inadequately controlled cardiovascular risk
factors and have intensified their treatment according to
current treatment guidelines over a 3 months period and
aimed to maintain this intensification over 2 years. The
primary aim was to investigate the impact of this interven-
tion on CIMT during these 2 years. The secondary aim
was to investigate whether the treatment intensification
has an impact on novel cardiovascular surrogate measure-
ments such as the number of endothelial progenitor cells,
endothelial function or selected biomarkers and if so,
whether they prove clinically useful as early predictors for
CIMTchanges after 2 years.
Materials and methods
Study design
We performed a single-center, prospective, open, 2-year
clinical trial. At baseline, after 3 months and after 2 years
patients were seen at the Division of Endocrinology and
Metabolism at the Medical University of Graz, Austria for
a detailed examination. Examinations were conducted
in the morning following an overnight fast. The subjectenrollment started in March 2008 and ended in May
2010. Data were first collected on a paper case report
form and were then transferred to electronic case report
forms.
Reporting the study conforms to STROBE along with
references to STROBE and the broader EQUATOR
guidelines [9].
Patients received a target oriented, intensified treat-
ment of risk factors according to current national treat-
ment guidelines (available at http://www.oedg.org). All
patients received personalized lifestyle counseling. After
3 months all modifiable risk factors were re-evaluated.
Between the 3 months visit and the 2 year follow up all
patients were regularly followed by their usual care pro-
vider and received regular phone calls by the study site
to discuss risk factor control and the usual care provider
was reminded of treatment targets if necessary in order
to maintain adequate cardiovascular risk factor control.
If risk factor management remained unsatisfactory, the
patient was invited for a follow-up visit at the diabetes
outpatient clinics of the Medical University of Graz. 24
months after inclusion into the study CIMT was measured
again.
Participants
Patients with type 2 diabetes mellitus without previous
vascular events were identified from the outpatient clinic
at the Division of Endocrinology and Metabolism at the
Medical University of Graz. Written informed consent
was obtained from all subjects.
Patients were eligible if they were 45 to 75 year old, had
type 2 diabetes mellitus with at least two insufficiently
controlled risk factors: i.e.: LDL-cholesterol >3.1 mmol/l,
blood pressure >140/90 mmHg (either or), HbA1c >7.5%
(>58 mmol/mol), all listed parameters could be treated
or untreated. Diabetes mellitus was defined as fasting
blood glucose ≥7.0 mmol/l or a history of established
diabetes according to WHO criteria [10]. Patients with
a history of any cardiovascular events, heart failure
(>NYHA II), serum creatinine >265.2 μmol/L, aspartat-
aminotransferase/alanine-aminotransferase >3-fold ULN
of the reference range and major psychiatric disorders
were excluded.
Primary outcome measurement
The primary outcome was the change in CIMT from base-
line to 2 years. High-resolution carotid artery ultrasound
measurements were obtained using a portable ultrasound
Acuson Cypress (Siemens Medical Solutions USA Inc.,
Mountainview, California). All recordings were performed
by a single, certified sonographer who had no access to
the baseline measurements at the time of follow up assess-
ment. The common carotid artery, carotid bulb, and in-
ternal as well as external arteries were examined. CIMT
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distal to the bifurcation over a length of 10 mm. Digital
images were electronically transferred to an offline
workstation where as a first step an automated quality
index of the image was assessed and if the predefined
quality criteria were met, CIMT measurements were
performed by using a dedicated analysis software (M’Ath,
Metris SRL, Argenteuil, France) in order to reduce meas-
urement variability. Mean CIMT was calculated as the
average of multiple measurements of the far wall IMT of
the left and right common carotid artery.
A 75 g oral glucose tolerance test was performed in all
subjects after a 12-h overnight fast at baseline and after
3 months.
Reactive hyperaemia index (RHI)
Endo-PAT 2000 (Itamar Medical Ltd., Caesarea, Israel) was
used to measure endothelium-dependent vaso-reactivity
as previously described [11].
Endothelial progenitor cells (EPCs)
Peripheral white blood cells were analysed for the ex-
pression of endothelial progenitor cell characterizing
surface markers by using flow cytometry as previously
described [12].
Symmetric dimethylarginine (SDMA) and asymmetric
dimethylarginine (ADMA)
We measured SDMA and ADMA in frozen EDTA
plasma (-20°C) by high-performance liquid chromatog-
raphy (HPLC) with solid phase extraction and precolumn
derivatization [13]. Within-day CVs for SDMA were 4.6%
(0.60 μmol/L) and 1.9% (1.0 μmol/L), and between-day
CVs were 9.8% (0.60 μmol/L) and 6.1% (1.0 μmol/L).
Within-day CVs for ADMA were 3.1% (0.62 μmol/L)
and 1.0% (2.0 μmol/L), and between-day CVs were 9%
(0.62 μmol/L) and 1.5% (2.0 μmol/L).
High sensitivity c-reactive protein (hs-CRP)
Hs-CRP was measured with a particle-enhanced immuno-
turbimetric assay (Roche Diagnostics GmbH, Mannheim,
Germany), with a detection limit of 0.1 mg/l.
PROCAM (PROspective cardiovascular Münster) risk score
The PROCAM-algorithm estimates the risk for acute
coronary events (myocardial infarction, sudden cardiac
death) within 10 years. The calibrated risk score includes:
age, LDL- cholesterol, smoking, HDL-cholesterol, systolic
blood pressure, family history of premature myocardial
infarction, diabetes mellitus, and triglycerides [14].
UKPDS risk engine
The UKPDS Risk Engine 2.0 is a type 2 diabetes specific
risk calculator based on 53,000 patient years of datafrom the UK Prospective Diabetes Study. The UKPDS
risk engine provides risk estimates and 95% confidence
intervals, in individuals with type 2 diabetes not known
to have heart disease, for non-fatal and fatal coronary
heart disease, for fatal coronary heart disease, for non-
fatal and fatal stroke as well as for fatal stroke. These
can be calculated for any given duration of type 2
diabetes based on current age, sex, ethnicity, smoking
status, presence or absence of atrial fibrillation and levels
of HbA1c, systolic blood pressure, total cholesterol and
HDL cholesterol [15].
Glucose lowering
Patients were treated according to current international
treatment guidelines for type 2 diabetes mellitus at this
time. The generally recommended treatment target for
HbA1c was ≤6.5% (≤48 mmol/mol) with a personalized
treatment target approach. Thus, the first-line therapy
was metformin followed by a second oral antihypergly-
caemic agent (AHA) and extended to a triple oral ther-
apy if required. If no sufficient glycaemic control was
achieved with oral AHAs, insulin therapy was added. If
HbA1c was >8.0% (>64 mmol/mol) at the baseline visit
while the patient was on no or one oral AHA only, treat-
ment was intensified by commencing two additional
AHAs simultaneously.
Lipid treatment
The LDL-cholesterol target was <2.6 mmol/l in all patients
included. A statin was used as first-line medication and
the dose escalated if required. Another lipid lowering
agent was added if the LDL-cholesterol target was not
reached within 3 months.
Blood pressure treatment
A blood pressure of ≤130/80 mmHg (preferably serial
home measurements if available, otherwise office reading)
was the treatment target. First-line therapy was targeting
the renin-angiotensin-system (i.e. angiotensin converting
enzyme inhibitors or angiotensin receptor blocker). Fur-
ther agents were added if required.
Statistical analysis
The distribution of the continuous variables was evaluated
by a Kolmogorov-Smirnov test. The paired student’s t-test
or the Wilcoxon signed-rank test was used to compare the
measurements before and after multifactorial treatment,
as appropriate, depending on the distribution of the data.
Linear mixed effects models were built with time in
months as influence variable (fixed effect) and patient-ID
as random effect to estimate trend over time for selected
risk factors to deal with the limited number of time points
available.
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ables. Correlations were made using a Pearson’s product
moment correlation coefficient.
A two-tailed p-value of less than 0.05 was considered
as statistically significant.
Additional, explorative statistical data analysis was
done building a linear multivariate regression model on
the progression of CIMT. Variable selection for influence-
variables to predict CIMT progression was based on
univariate regression modelling. Baseline values from
candidate variables and changes in these values from
baseline to 3-months with a p-value below 0.2 together
with age and sex (as potential confounder variables)
were included as influence variables into the linear
multivariate regression model with CIMT progression
(ΔCIMT) as outcome variable. Amongst others the fol-
lowing candidate variables were included for the linear
multivariate regression model: CIMT, triglycerides,
coronary heart disease (CHD) risk score, PROCAM risk
score, waist circumference, HDL-cholesterol, serum
creatinine, 2h-glucose, smoking, statin therapy – all
measured at baseline as well as changes in triglycerides
NTproBNP, HDL-cholesterol, 2h-glucose from baseline
to 3 months as well as statin therapy after 3 months
together with age and sex (as potential confounder
variables) (see the `List of parameters entering univariate
analysis´ section) were included into the multivariate re-
gression analysis with ΔCIMT as outcome variable. The
Model selection process for multivariate modelling
(which exposure variables to include in the final model)
was based on the Akaike Information Criterion using
backward selection. If one or more variables were highly
correlated, the less significant ones were excluded; the
variance inflation factor was used as a criterion for col-
linearity, with a cut off < 3. Only complete cases for can-
didate variables were included into modelling.
List of parameters entering univariate analysis
Asymmetric dimethylarginine (Baseline), Asymmetric
dimethylarginine (Δ), Age, Alanin-Aminotransferase (Base-
line), Alanin-Aminotransferase (Δ), Apolipoprotein B (Base-
line), Apolipoprotein B (Δ), Body mass index (Baseline),
Body mass index (Δ), CD34CD133 (Baseline), CD34CD133
(Δ), Coronary heart disease UKPDS risk engine 2.0
(Baseline), Coronary heart disease UKPDS risk engine
2.0 (Δ), Diabetes duration (Baseline), Global arginine
bioavailability ratio (Baseline), Global arginine bioavail-
ability ratio (Δ), Gamma Glutamyltransferase (Baseline),
Gamma Glutamyltransferase (Δ), Fasting blood glucose
(Baseline), Fasting blood glucose (Δ), Blood glucose 2h
(Baseline), Blood glucose 2h (Δ), urinary albumin (Base-
line), Urinary albumin (Δ), HbA1c (Baseline), HbA1c (Δ),
HDL-cholesterol (Baseline), HDL-cholesterol (Δ), HOMA
index (Baseline), HOMA index (Δ), Intima media thickness(Baseline), Fasting insulin (Baseline), Fasting insulin
(Δ), Serum creatinine (Baseline), Serum creatinine (Δ),
LDL-cholesterol (Baseline), LDL-cholesterol (Δ), Lipo-
protein (a) (Baseline), NTproBNP (Baseline), NTproBNP
(Δ), Reactive hyperaemia index (Baseline), reactive hyper-
aemia index (Δ), Blood pressure diastolic (Baseline), Blood
pressure diastolic (Δ), Blood pressure systolic (Baseline),
Blood pressure systolic (Δ), Sex, Smoking (Baseline),
Triglycerides (Baseline), Triglycerides (Δ), 25-OH-vitamin
d3 (Baseline), 25-OH-vitamin d3, Waist circumference
(Baseline).
Explained variance of the multivariate model above 30%
and p-value <0.05 were taken to be predictive powerful
and useful to interpret.
Univariate and multivariate linear modelling was done
using the statistical software R version 2.15, whereas fur-
ther statistical analyses were performed by using SPSS
19.0 software (SPSS Inc, Chicago, Ill).
Results
Patients
111 subjects were screened for the study between March
2008 and May 2010. Study inclusion criteria were met
by 97 patients who were enrolled in the study. (For patient
flow chart see Figure 1). Baseline characteristics of com-
pleters and non-completers of the study are presented in
Table 1. Non-completers were more often females and
smokers, were older and had slightly higher HbA1c values,
but did not differ otherwise from those who have com-
pleted the study.
Participants (38 f/59 m) were in mean 60 years old with
mean diabetes duration of 7.7 years. An extensive list of
baseline characteristics is provided in Tables 1 and 2.
Risk factor management
In order to treat risk factors to target, the use of oral
AHAs, insulin, statins and blood pressure lowering
medication was significantly increased over the 3 months
period of treatment intensification. Detailed changes in
pharmacological treatments are outlaid in Table 3. All
targeted risk factors significantly improved from base-
line to 3 months. Although an increase in all risk factor
levels over the 21 months following the intensive treat-
ment period was noted, the mean HbA1c, LDL-cholesterol
and blood pressure levels at 24 months were still signifi-
cantly lower than at the beginning of the study (Table 2).
In addition, triglycerides improved from baseline to 3
months (p = 0.007), however, the reduction was not
sustained until the 2 years follow up visit (p = 0.292).
Primary outcome
Multifactorial risk factor intervention was associated
with a significant regression in mean CIMT from base-
line to study end (0.883 ± 0.120 mm vs. 0.860 ± 0.130
77 Completed follow-up study
Visit 1 (Baseline)
Visit 3 (2 years)
Visit 2 (3 months)
Screening 
Pre-Screening Assessed for eligibility 
94 Completed Visit 2 
97 Were assigned to receive 
multifactorial treatment
14 were excluded 
- Not meeting inclusion criteria 
3 were excluded 
- 1 Died (car accident)
- 2 Withdrew informed 
17 were excluded 
- 17 Withdrew informed consent 
Figure 1 Study flow chart.
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(66%) showed a regression or no measureable change of
CIMT after 2 years, 26 (34%) progressed (0.061 ± 0.044
mm). There were no significant differences in baseline
characteristics between patients with a regression and
those with progression of CIMT after 2 years.
Mean CIMT significantly correlated with age at base-
line (r = 0.365; p < 0.001), duration of diabetes (r = 0.273;
p = 0.007) and systolic blood pressure (r = 0.320; p = 0.001).
In addition mean CIMT significantly correlated with all
UKPDS risk engine scores (p < 0.001 for all) and CIMT
changes from baseline to 2 years correlated with changes
in triglycerides (r = 0.292; p = 0.012).
Endothelial function and endothelial progenitor cells
No associations between RHI and cardiovascular risk
factors as well as changes in RHI and changes in risk
factors were observed. Likewise no changes were ob-
served in other measures of endothelial function such
as ADMA and SDMA. We also assessed the number of
CD133/VEGF-R2 positive cells in peripheral blood be-
fore and after the intervention. No changes in the
number of endothelial progenitor cells were observed
(15 (IQR 7-28)/106 at baseline versus 17 (7-32)/106 at
12 weeks, p = 0.164).
The only parameter that significantly improved from
baseline (3.5 mg/L, IQR 2.1-5.9) to 3 months (2.2, IQR
1.2-4.1, p < 0.001) was high sensitive C-reactive protein.
Predictors of CIMT progression
The relation from progression in CIMT (ΔCIMT) to po-
tential risk factors was analyzed in a linear multivariateregression model. This model was built on ΔCIMT as
the outcome variable and a set of predictor variables. The
predictor variables were selected based on univariate re-
gression modelling, with ΔCIMT as outcome-variable. We
identified 14 variables with a p-value below 0.2 in the uni-
variate model, which were selected for the final multifac-
torial regression model. Additionally, the variables sex and
age were included as potential confounder-variables for
model adjustment as well as statin treatment at baseline
and 3 months. The linear multivariate regression model
did not yield statistical significance for CIMT prediction at
two years (p = 0.16) (Table 4).
Discussions
Our study demonstrated that an intensive multifactorial
risk factor intervention over 3 months in a specialized
diabetes center can lead to sustainably improved risk
factor control and a regression of carotid intima media
thickness over the period of 2 years. Neither established
risk factors nor endothelial function or other novel bio-
markers and their changes during a 3 months period of
intensified risk factor management were able to explain
changes of carotid atherosclerosis.
The STENO-2 study was a trial investigating multifactor-
ial interventions, targeting hypertension, hyperglycaemia
and hyperlipidemia which impressively demonstrated the
superiority of an intensive risk factor management as
compared to a less intensive approach with respect to
non-fatal and fatal cardiovascular event reduction [2,16].
Despite the fact that intensive risk factor control deterio-
rated somewhat after the first 3 months in our study,
24.4% of participants achieved an HbA1c target of <6.5%
Table 1 Baseline-characteristics compared completers and non-completers of the study
Completers (n = 77) Non-completers (n = 20) p-value
Sex (female/male) 27/50 9/11 0.001
Age (years) 60 ± 8 65 ± 10 0.048
Height (cm) 170 ± 9 167 ± 9 0.061
Weight (kg) 91 ± 15 91 ± 18 0.989
Smokers 25 (25.8%) 8 (40%) 0.002
Packyears (years) 31 (12 – 56) 26 (10 -58) 0.599
Hip circumference (cm) 113 ± 9 112 ± 9 0.717
Waist circumference (cm) 109 ± 12 107 ± 13 0.396
Blood pressure systolic (mmHg) 154 ± 17 146 ± 19 0.138
Blood pressure diastolic (mmHg) 90 ± 9 88 ± 11 0.473
Duration of diabetes mellitus (years) 7.7 ± 6.8 7.5 ± 5.4 0.897
HbA1c % (mmol/mol) 8.2 ± 1.1% (66 ± 12) 8.6 ± 0.7% (70 ± 8) 0.049
Total cholesterol (mmol/l) 4.93 ± 1.11 5.02 ± 1.11 0.785
Low density lipoproteins (mmol/l) 2.79 ± 1.11 2.79 ± 1.12 0.937
High density lipoproteins (mmol/l) 1.14 ± 0.36 1.11 ± 0.46 0.738
CIMT (mm) 0.883 ± 0.120 0.875 ± 0.171 0.840
RHI 1.70 (1.46 – 2.08) 1.72 (1.38 – 2.07) 0.590
CD133 + VEGF-R2 (per 106 lymphomonocytes) 15 (7 – 28) 14 (5 – 21) 0.514
ADMA (μM/L) 0.625 ± 0.080 0.606 ± 0.082 0.313
SDMA (μM/L) 0.562 ± 0.131 0.543 ± 0.110 0.445
Serum creatinine (μmol/l) 88.4 ± 26.5 84.0 ± 36.0 0.604
Alanin-Aminotransferase (U/l) 29 (21 – 40) 24 (21 – 39) 0.836
Gamma Glutamyltransferase (U/l) 35 (21 – 59) 28 (21 – 38) 0.824
Aspartat-Aminotransferase (U/l) 27 (21 – 36) 49 (28 – 91) 0.246
Data are presented as means ± standard deviation or, in the case of a skewed distribution, as medians (interquartile ranges). ADMA = asymmetric
dimethylarginine; SDMA = symmetric dimethylarginine; HbA1c = glycated hemoglobin A1c; cIMT = common carotid artery intima-media thickness; RHI = Reactive
hyperaemia Index.
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and 58.5% a systolic blood pressure <130 mmHg at two
years, representing higher percentages for systolic blood
pressure and HbA1c target achievement than in the
STENO-2 study or the recently published interim analysis
of the MIND.IT study, a cluster randomized trial evaluat-
ing the feasibility and effectiveness of intensive multifac-
torial risk factor intervention in T2DM [17].
CIMT is an independent predictor of future cardio-
vascular events and is often used as a surrogate marker
for the presence of cardiovascular disease [18] and fu-
ture vascular events [19]. Baldassarre et al. have recently
shown that fast progression over a 15 months period
was associated with an increased subsequent vascular
event risk [5].
They investigated subjects with at least 3 cardiovascular
risk factors and have observed a progression in all CIMT
measurements over 15 months. A sub-study of the Out-
come Reduction with an Initial Glargine Intervention
(ORIGIN) trial investigated the effect of insulin glargineand n-3 fatty acids on carotid IMT [20]. The CIMT at
baseline in the ORIGIN study was 0.88 ± 0.25 mm and
therefore similar to the 0.883 ± 0.120 mm observed in our
study. Although there was a trend towards a somewhat
reduced IMT progression rate in the glargine treated
group, it did not reach statistical significance. Of note,
the annual CIMT progression observed in the placebo
group was 0.026 ± 0.002 mm (maximum CIMT for 12
carotid artery segments). Analyses from lipid and blood
pressure lowering trials, which included only a small
number of subjects with diabetes, showed somewhat
lower annual progression rates (0.015 ± 0.053 mm) [21].
When interpreting our study results, one needs to
keep in mind that, as observed in the ORIGIN sub-study
the natural course would have been a mean progression
of about 0.050 mm (i.e. 5.6%) in the overall cohort over
these 2 years rather than a 2.6% regression as observed
in our study.
Previous studies demonstrated that single risk factor
intervention like glucose lowering [22], lipid lowering








(baseline to 3 months)
p-value
(baseline to 2 years)
Traditional risk factors
Total cholesterol (mmol/l) 4.93 ± 1.11 4.28 ± 1.11 4.54 ± 1.29 <0.001 0.007
Low density lipoproteins (mmol/l) 2.79 ± 1.11 1.96 ± 1.01 2.40 ± 1.11 <0.001 0.008
High density lipoproteins (mmol/l) 1.14 ± 0.36 1.26 ± 0.34 1.24 ± 0.36 <0.001 0.001 *
Triglycerides (mmol/l) 1.86 1.46 1.64 <0.001 0.205
(1.31 – 2.66) (1.06 – 2.23) (1.27 -2.52)
ApoA1 (g/l) 1.43 ± 0.22 1.46 ± 0.23 - 0.065 -
ApoB (g/l) 0.94 ± 0.23 0.81 ± 0.25 - <0.001 -
Blood pressure systolic (mmHg) 154 ± 17 135 ± 12 139 ± 16 <0.001 <0.001 *
Blood pressure diastolic (mmHg) 90 ± 9 82 ± 8 86 ± 16 <0.001 0.005
HbA1c % (mmol/mol) 8.2 ± 1.1 7.2 ± 0.9 7.7 ± 1.1 <0.001 0.001
(66 ± 12) (54 ± 14) (61 ± 12)
Fasting blood glucose 9.9 ± 2.7 8.1 ± 2.3 - <0.001 -
2h blood glucose (mmol/l) 18.2 ± 4.9 16.0 ± 4.5 <0.001
BMI (kg/m2) 31.8 ± 4.7 31.4 ± 5.3 31.2 ± 4.6 0.465 0.807
Biomarkers
RHI 1.70 1.59 - 0.072 -
(1.46 – 2.08) (1.38 – 1.94)
CD133 + VEGF-R2 (per 106 lymphomonocytes) 15 17 - 0.164 -
(7 – 28) (9-32)
ADMA (μM/L) 0.625 ± 0.080 0.627 ± 0.075 - 0.835 -
SDMA (μM/L) 0.562 ± 0.131 0.599 ± 0.145 - 0.001 -
hsCRP (mg/L) 3.5 2.2 - <0.001 -
(2.1 – 5.9) (1.2 – 4.1)
NTproBNP (pg/mL) 104.8 ± 121.7 97.7 ± 103.6 - 0.412 -
Data are presented as means ± standard deviation or, in the case of a skewed distribution, as medians (interquartile ranges).
NTproBNP = N-terminal Pro B-Type Natriuretic Peptide; HbA1c = glycated haemoglobin A1c; HOMA–IR = Homeostasis Model Assessment of Insulin Resistance;
BMI = body mass index; ADMA = asymmetric dimethylarginine; SDMA = symmetric dimethylarginine; hsCRP = high sensitivity C-reactive protein; RHI = Reactive
hyperaemia Index; *p-value for trend ≤0.05.
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but to the best of our knowledge this is the first pro-
spective study showing the impact of multifactorial risk
factor intervention on CIMT in subjects with type 2 dia-
betes. CIMT, in our cohort, was significantly associated
with age (p = 0.012), duration of diabetes (p < 0.001) as
well as systolic blood pressure (p = 0.001).
Endothelial function as measured by the EndoPAT
technique was not associated with the overall cardiovas-
cular risk and did not improve with multifactorial risk
factor intervention. Previous studies in patients with
type 2 diabetes mellitus have also shown conflicting re-
sults with regard to endothelial function using statins
[25] or blood pressure lowering medication [26]. How-
ever, it has been questioned whether the EndoPAT mea-
surements are directly comparable to other assessments
of endothelial dysfunction, like flow mediated dilation,since hyperaemia is captured by finger probes as com-
pared to vasodilation assessment of larger arteries [27].
We assessed further markers of endothelial function
like ADMA and SDMA, which both turned out not to
improve by the intensified treatment or to be of any help
regarding the prediction of atherosclerosis progression
in our cohort.
Although a previous study in 28 subjects demonstrated
an increase of EPCs by multifactorial treatment in patients
with type 2 diabetes as assessed by an in-vitro culture
assay [12], we were not able to reproduce this finding
when measuring CD133/VEGF-R2+ cells by FACS
analysis.
With the intention of a personalized treatment approach
there is an urgent need to identify novel biomarkers for
cardiovascular risk prediction in subjects with diabetes.
Since currently a large number of outcome trials is








(baseline - 3 months)
p-value
(baseline - 2 years)
Glucose lowering treatment (%)
Metformin 62.9 75.5 67.1 0.001 0.655
Acarbose 3.1 2.1 1.2 0.320 0.317
Sulfonylureas 24.7 29.8 19.5 0.158 0.285
Glitazones 11.3 25.5 19.5 <0.001 0.058
DPP-IV Inhibitors 9.3 19.1 26.8 0.002 0.001
Insulin 26.8 32.3 29.3 0.027 0.105
Other OADs 3.1 3.3 2.4 1.000 0.564
Lipid lowering treatment (%)
Statins 35.1 73.4 68.3 <0.001 <0.001
Ezetimibe 4.1 4.3 1.2 1.000 0.157
Fibrates 6.2 7.5 4.8 0.564 1.000
Antihypertensive treatment (%)
ACE-Inhibitors 46.4 61.7 46.3 <0.001 1.000
Ca-channel blockers 21.6 47.9 46.3 <0.001 <0.001
Beta-blockers 35.1 40.4 42.7 0.102 0.109
AT2-blockers 21.6 28.7 30.0 0.033 0.132
Other Antihypertensives 37.1 46.8 42.5 0.020 0.516
OAD = oral antidiabetic drugs; DPP-IV = Dipeptidylpeptidase IV; ACE = angiotensin converting enzyme; AT2 = angiontensin-2-receptor antagonist;
ca-channel = calcium-channel.
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marker samples, we expect a plethora of opportunities
for targeted and untargeted biomarker research initia-
tives in this field within the next years.
Strengths and limitations
The major strengths of our trial are that we included a
representative group of subjects with type 2 diabetes
without cardiovascular events and that we were able to
achieve currently recommend treatment targets in more
patients than in other studies (STENO-2, MIND.IT) and
the follow-up period of two 2 years for the primary out-
come measurement chosen is reasonably long.
One limitation of our study is the uncontrolled design
of our trial. However, the aim of this trial was to assess
CIMT progression in subjects with type 2 diabetes
treated according to current guidelines and to possibly
identify early markers predictive of atherosclerosis pro-
gression rather than comparing different treatment tar-
gets in these subjects. In addition it would have been
unethical to recommend less stringent treatment targets
to a control group than currently suggested by treatment
guidelines.
Our baseline CIMT measurement is similar to the one
of the ORIGIN sub-study. Therefore the placebo group
of the ORIGIN trial could be adopted as a control group,
demonstrating the natural course of CIMT in subjectswith dysglycaemia over time and helps putting our results
into perspective.
Another limitation is that although CIMT is associated
with risk for future cardiovascular events, previous studies
have shown that adding CIMT to established risk calcula-
tors does not improve risk prediction [29]. In this study
we did not investigate the additional predictive value of
CIMT for cardiovascular events but the change of CIMT
by intensified risk factor treatment. Spence et al. have pre-
viously suggested that the extend of risk factor treatment
should be determined by atherosclerosis progression rate
rather than by the same treatment target for all subjects,
however, this approach needs to be tested in a dedicated
trial [30].
While CIMT is a measure of early atherosclerosis,
carotid plaques reflect a more advanced stage of the
disease [31]. Despite a correlation between CIMT and
plaque volume measurements and the fact that both
are predictors of cardiovascular events, they are not
interchangeable and are determined by different risk
factor patterns [32-35]. For this study we have chosen
CIMT because of the advantage of standardization of
measurement and the plethora of randomized controlled
trials using this surrogate marker [21].
In summary we were able to show an overall regres-
sion of mean CIMT by multifactorial risk factor inter-
vention in subjects with T2DM. However, neither baseline
Table 4 Model-coefficients of predictor variable of the
linear multivariate regression model with ΔCIMT as
outcome variable (BMI was excluded because of
high-correlation with Waist)
β ̂ 95% CI p-value
Waist circumference (Baseline) 0.19 (−0.05 to 0.44) 0.12
HDL-cholesterol (Baseline) 0.10 (−0.26 to 0.46) 0.56
Triglycerides (Baseline) −0.02 (−0.06 to 0.02) 0.33
Serum creatinine (Baseline) −1.32 (−15.08 to 12.45) 0.85
Smoking (Baseline) −4.15 (−12.53 to 4.22) 0.32
Blood glucose 2h (Baseline) 0.00 (−0.04 to 0.04) 0.98
CHD risk score (Baseline) −0.25 (−0.76 to 0.26) 0.33
PROCAM risk score (Baseline) 0.20 (−0.21to 0.6) 0.34
Statin therapy (Baseline) −3.95 (−10.78 to 2.87) 0.25
CIMT (Baseline) −11.29 (−37.99 to 15.4) 0.40
Δ HDL-cholesterol −0.02 (−0.15to 0.12) 0.82
Δ Triglycerides 0.00 (−0.05 to 0.05) 0.99
Δ NTproBNP −0.02 (−0.04 to 0) 0.09
Δ Blood glucose 2h 0.04 (−0.11 to 0.2) 0.58
Sex −1.30 (−11.66 to9.06) 0.80
Age (Baseline) 0.02 (−0.69 to 0.72) 0.96
Statin therapy (3 Months) −3.86 (−10.8 to 3.08) 0.27
CHD = Coronary Heart Disease (UKPDS risk engine 2.0); PROCAM – Prospective
Cardiovascular Münster; IMT – Intima Media Thickness; NTproBNP = N-terminal
Pro B-Type Natriuretic Peptide; β̂ = estimates of beta coefficient;
CI = confidence interval.
Male gender, statin therapy and smoking were assigned a value of 1. Female
gender, no statin therapy and non-smoking were assigned a value of 0.
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fied treatment period of established risk factors, endo-
thelial function marker, endothelial progenitor cells or
inflammation were able to predict changes in the pro-
gression of carotid atherosclerosis. Our data suggest
that besides novel, yet to be identified biomarkers,
changes in CIMT might be used as a measure of treat-
ment response and could help identify subjects with
high residual cardiovascular risk despite guideline com-
pliant treatment but this approach would need to be
tested in future trials.
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